The clinical impact of EGFR mutation subtypes in early-stage NSCLC are described, with EGFR Del19, compared to L858R, being associated with younger onset, larger consolidation size, higher frequency of pure-solid tumors, significant correlation with higher pathological stage and poorer PFS [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.